JGP Global Gestao de Recursos Ltda.
Long book
$22.3M
Q1 2026
Positions
23
Top-10 weight
86%
concentration
Last quarter
-2.6%
SPY +14.8%
Turnover
48%
of book per quarter
Strategy in plain words
auto-generated from filingsJGP Global Gestao de Recursos Ltda. is a concentrated fundamental stock-picker, running a $22.3M US long book across 23 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: STONECO LTD-A, XP INC - CLASS A, NU HOLDINGS LTD/CAYMAN ISL-A, ELI LILLY & CO, ABBVIE INC.
Over the last 9 quarters its long book ran on average 0.6pp per quarter behind the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-14.1%
Q2 2024
+2.6%
Q3 2024
-14.7%
Q4 2024
+8.5%
Q1 2025
+38.0%
Q2 2025
+23.2%
Q3 2025
-13.4%
Q4 2025
+7.2%
Q1 2026
-2.6%
Sector allocation
Financials 39%
Technology 33%
Healthcare 25%
Other 2%
Consumer discretionary 1%
Long book by quarter
What does JGP Global own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| STNE STONECO LTD-A | Technology | 475.1K | $6.7M | 30.1% | -82.1% |
| XP XP INC - CLASS A | Financials | 259.5K | $4.9M | 22.2% | +3.8% |
| NU NU HOLDINGS LTD/CAYMAN ISL-A | Financials | 235.6K | $3.4M | 15.2% | -19.4% |
| LLY ELI LILLY & CO | Healthcare | 1.2K | $1.1M | 5.1% | +1.1% |
| ABBV ABBVIE INC | Healthcare | 3.1K | $668K | 3.0% | +0.5% |
| INCY INCYTE CORP | Healthcare | 5.6K | $529K | 2.4% | -38.2% |
| JNJ JOHNSON & JOHNSON | Healthcare | 2.1K | $521K | 2.3% | +0.4% |
| BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 6.2K | $374K | 1.7% | +0.4% |
| TMO THERMO FISHER SCIENTIFIC INC | Other | 704 | $346K | 1.6% | +0.9% |
| ISRG INTUITIVE SURGICAL INC | Healthcare | 750 | $346K | 1.6% | +0.9% |
| GILD GILEAD SCIENCES INC | Healthcare | 2.3K | $325K | 1.5% | +0.4% |
| ABT ABBOTT LABORATORIES | Healthcare | 3.1K | $318K | 1.4% | +1.2% |
| NVDA NVIDIA CORP | Technology | 1.5K | $265K | 1.2% | -36.8% |
| MCK MCKESSON CORP | Consumer discretionary | 284 | $246K | 1.1% | +0.7% |
| VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 537 | $240K | 1.1% | +0.9% |
| MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 433 | $227K | 1.0% | -30.7% |
| ZTS ZOETIS INC | Healthcare | 1.8K | $212K | 1.0% | +0.5% |
| INSM INSMED INC | Healthcare | 1.3K | $212K | 1.0% | -48.1% |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 3.3K | $205K | 0.9% | +0.8% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 8, 2026 | 29 | $23.2M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Jan 26, 2026 | 49 | $169.5M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Oct 24, 2025 | 36 | $172.0M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Jul 22, 2025 | 45 | $204.3M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 9, 2025 | 35 | $130.8M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Jan 24, 2025 | 40 | $43.9M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 1, 2024 | 40 | $51.2M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 2, 2024 | 41 | $78.8M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 9, 2024 | 61 | $155.6M | canonical | SEC ↗ |
Similar funds
Sanders Capital, LLCGATES FOUNDATION TRUSTEAGLE CAPITAL MANAGEMENT LLCWoodbridge Co LtdAlecta Tjanstepension OmsesidigtMubadala Investment Co PJSCH&H International Investment, LLCNewlands Management Operations LLCINVESTOR ABIndependent Franchise Partners LLPPineStone Asset Management Inc.Pentwater Capital Management LP